Coherus BioSciences's guest appearances

Coherus BioSciences

Biotech 2050 Podcast

TD Ameritrade Network

Liz Ann Sonders

Sheryl Sandberg

Carrie Schwab-Pomerantz

Peter Diamandis

John Mackey

Ralph Lauren

Jack Dorsey

Robert Gould

Kevin O'Leary

Kraft Heinz

Jim Burns

Charles Schwab

Eli Lilly

David Berry

Clark Kendall

OwlTail

Brad Loncar discusses the broader outlook for the biotech sector, on what he calls one of the best days he has seen "in ages". Two of his stocks to watch within the sector are MacroGenics and Coherus BioSciences, and he talks through some of the opportunities that lay ahead in these two names. 

<p>Brad Loncar discusses the broader outlook for the biotech sector, on what he calls one of the best days he has seen "in ages". Two of his stocks to watch within the sector are MacroGenics and Coherus BioSciences, and he talks through some of the opportunities that lay ahead in these two names. </p>

Why MacroGenics (MGNX), Coherus BioSciences (CHRS) Should Be On Your Biotech Radar

Glenn Rosen

Dr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University. He led a basic and translational research laboratory-his research focused on the study of dysregulated signaling in fibrosis and mechanisms of apoptosis resistance in solid tumors. He also led the clinical Interstitial Lung Disease Program at Stanford. Dr. Rosen joined Bristol-Myers Squibb (BMS) in September 2014 as a Medical Director in the Early Clinical and Translational Research Group, where he led the Phase 2 program of a lysophosphatidic acid receptor antagonist for the treatment of pulmonary fibrosis. This was followed by appointment as Therapeutic Area Head of Fibrosis and Genetically Defined Diseases. In 2016 he was selected as Head, Discovery Fibrosis Biology at Bristol-Myers Squibb, where he led the early discovery and development, and translation of pre-clinical compounds, with a disease concentration in liver and lung fibrosis. Dr. Rosen joined Coherus Biosciences, Redwood City, CA, in April, 2019, where he leads the pre-clinical and translational sciences small molecule program, which is focused on development of a novel selective PPARγ modulator for the treatment of NASH.

21. Glenn Rosen, MD, Senior VP, Pre-Clinical Translational Sciences, Coherus BioSciences